Current research focuses on enhancing the efficacy of immune checkpoint blockade combined with chemotherapy in HER2-negative gastrointestinal adenocarcinoma. This trial evaluates different first-line chemotherapy regimens in combination with immunotherapy.
- Sylvie Lorenzen
- Thorsten Oliver Goetze
- Salah-Eddin Al-Batran
